NEURACLE SCIENCE CO. LTD

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

NEURACLE SCIENCE CO. LTD - overview

Established

2015

Location

Seoul, -, South Korea

Primary Industry

Biotechnology

About

Founded in 2015 and based in Seoul, South Korea, Neuracle Science. Co. , LTD. operates as a biopharmaceutical company that develops pharmaceutical treatments of neurodegenerative diseases.


In May 2024, Neuracle Science Co. , LTD. raised KRW 7. 6 billion of pre-IPO funding from investors Arche Investment and Susung Asset Management, along with the participation of QUAD Investment Management.


Neuracle Science develops treatments for severe neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and neurogenic bowel dysfunction. The company’s research includes candidates like NS101, an antibody currently in clinical development for Alzheimer’s disease and other neurodegenerative conditions, and NS200, which targets colonic motility disorders and neurogenic bowel dysfunction. Their development pipeline also features advanced antibody therapeutics, utilizing proprietary Fc Engineering to enhance drug efficacy. These solutions aim to improve nerve regeneration, synapse formation, and neural environment remodeling.


Current Investors

Shinhan Securities, NH Investment & Securities, BNK Asset Management

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Mental Health Services, Pharmaceutical Research & Development

Website

www.neuracles.com

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.